Boston, Massachusetts 02114


Purpose:

The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).


Study summary:

This is a single center, 13-week, outpatient, randomized, double-blind, placebo-controlled, parallel group, pilot study of topiramate in subjects with Sleep-Related Eating Disorder (SRED). The primary objective of this study is to investigate the efficacy and safety of topiramate compared to placebo in the treatment of Sleep-Related Eating Disorder. SRED is a disorder that consists of out of control eating during the night with little or no awareness of the events. In this study we are comparing topiramate to placebo. A placebo is a pill that looks exactly like the study drug, but it does not have any active drug in it. Topamax (topiramate) is approved by the U.S. Food and Drug Administration (FDA) as a therapy for epilepsy, but topiramate has not been approved by the FDA for SRED.


Criteria:

Inclusion Criteria: - Adults 18-65 - Diagnosis of SRED - Must be able to swallow capsules and follow instructions Exclusion Criteria: - Women who are pregnant or lactating - Other sleep disorders - Kidney or Liver disease - Night shift workers - Previous history of Topiramate or Topamax use for any condition


NCT ID:

NCT00606411


Primary Contact:

Principal Investigator
John W Winkelman, MD, PhD
Massachusetts General Hospital

Leslie Mei
Phone: 617-643-6026
Email: lamei@partners.org


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02114
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 22, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.